Stephan Ehrhardt1, Anton P Porsteinsson2, Cynthia A Munro3, Paul B Rosenberg3, Bruce G Pollock4, Davangere P Devanand5, Jacobo Mintzer6, Tarek K Rajji4, Zahinoor Ismail7, Lon S Schneider8, Sheriza N Baksh9, Lea T Drye9, Dimitri Avramopoulos10, David M Shade9, Constantine G Lyketsos3. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: sehrhar6@jhu.edu. 2. Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. 3. Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. 4. Campbell Family Research Institute and Division of Adult Neurodevelopment and Geriatric Psychiatry, CAMH, Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 5. Division of Geriatric Psychiatry, New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, New York, NY, USA. 6. Roper St. Francis Research and Innovation Center, Charleston, SC, USA; Medical University of South Carolina, College of Health Professionals and Ralph H Johnson VA Medical Center, Charleston, SC, USA. 7. Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Department of Clinical Neurosciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada. 8. Departments of Psychiatry and the Behavioral Sciences and Neurology, University of Southern California Keck School of Medicine and the University of Southern California Leonard Davis School of Gerontology, Los Angeles, CA, USA; Department of Neurology, University of Southern California Keck School of Medicine and the University of Southern California Leonard Davis School of Gerontology, Los Angeles, CA, USA. 9. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 10. Department of Psychiatry and Behavioral Sciences, Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
INTRODUCTION: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. METHODS: S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). DISCUSSION: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).
INTRODUCTION: Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. METHODS: S-CitAD is a NIH-funded, investigator-initiated, randomized, multicenter clinical trial. Participants receive a structured psychosocial intervention (PSI) as standard of care. Participants without sufficient response to PSI are randomized to receive 15 mg escitalopram/day or a matching placebo in addition to PSI. Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC). DISCUSSION: S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).
Authors: L S Schneider; J T Olin; R S Doody; C M Clark; J C Morris; B Reisberg; F A Schmitt; M Grundman; R G Thomas; S H Ferris Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: Lon S Schneider; Constantine Frangakis; Lea T Drye; D P Devanand; Christopher M Marano; Jacob Mintzer; Benoit H Mulsant; Cynthia A Munro; Jeffery A Newell; Sonia Pawluczyk; Gregory Pelton; Bruce G Pollock; Anton P Porsteinsson; Peter V Rabins; Lisa Rein; Paul B Rosenberg; David Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos Journal: Am J Psychiatry Date: 2016-01-15 Impact factor: 18.112
Authors: Mitchell K P Lai; Shirley W Y Tsang; Paul T Francis; Margaret M Esiri; Janet Keene; Tony Hope; Christopher P L-H Chen Journal: Brain Res Date: 2003-06-06 Impact factor: 3.252
Authors: Martin Steinberg; Huibo Shao; Peter Zandi; Constantine G Lyketsos; Kathleen A Welsh-Bohmer; Maria C Norton; John C S Breitner; David C Steffens; Joann T Tschanz Journal: Int J Geriatr Psychiatry Date: 2008-02 Impact factor: 3.485
Authors: Zahinoor Ismail; Byron Creese; Dag Aarsland; Helen C Kales; Constantine G Lyketsos; Robert A Sweet; Clive Ballard Journal: Nat Rev Neurol Date: 2022-01-04 Impact factor: 44.711
Authors: Esther S Oh; Paul B Rosenberg; Gail B Rattinger; Elizabeth A Stuart; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos Journal: J Am Geriatr Soc Date: 2020-12-31 Impact factor: 5.562